For example, how will transplanted human iPS cell derivatives behave in terms of cellfate and safety long-term in clinically relevant transplantation settings in rodents or larger animals that are good models for humans?
Two researchers at Harvard's Stem Cell Institute, David Scadden and Leonard Zon, contributed two compounds in midstage human tests that Fate Therapeutics believes could prove that traditional medicines can work on stem cells.